Press Releases BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 19/02/2026 am IST			5-day change	1st Jan Change
61.83 ^USD	+3.14%		+2.52%	+4.04%

18/02	Tarsus Pharmaceuticals, Inc. Appoints David E. I. Pyott to Its Board of Directors and Chairperson of Commercial Committee and as Member of Nominating Committee and Compensation Committee of the Board, Effective on February 18, 2026	CI
13/02	BioMarin Pharmaceutical Inc. Announces Closing of Private Offering of Senior Notes	CI

Press Releases

17/02	BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET	PR
13/02	BioMarin Announces Closing of Private Offering of Senior Notes	PR
30/01	BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility	PR
26/01	BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility	PR
13/01	BioMarin Appoints Arpit Davé Chief Digital and Information Officer	PR
09/01	BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA	PR
08/01	Veeva and BioMarin Form Long-Term Strategic Partnership	PR
19/12	BioMarin Pharmaceutical : Business Update	PU
11/11	BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England	PR
29/25/29	FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria	PR
28/25/28	BioMarin: Q3 Earnings Snapshot	AQ
28/25/28	BioMarin Pharmaceutical : Third Quarter 2025 Presentation	PU
28/25/28	BioMarin Pharmaceutical : Third Quarter 2025 Presentation	PU
28/25/28	BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update	PR
23/25/23	BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET	PR
08/25/08	BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting	PR
06/25/06	BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism	PR
27/25/27	BioMarin to Participate in Upcoming Investor Conferences	PR
05/25/05	BioMarin Pharmaceutical : Second Quarter 2025 Presentation	PU
05/25/05	BioMarin: Q2 Earnings Snapshot	AQ
05/25/05	BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS	PR
01/25/01	BioMarin Announces Appointment of Ian T. Clark to Board of Directors	PR
22/25/22	BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET	PR
25/25/25	BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress	AQ
24/25/24	BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Pharmaceuticals

Press Releases

Filters